ATE432997T1 - Therapieüberwachung für tumoren unter benutzung acc133 mrna - Google Patents
Therapieüberwachung für tumoren unter benutzung acc133 mrnaInfo
- Publication number
- ATE432997T1 ATE432997T1 AT05710924T AT05710924T ATE432997T1 AT E432997 T1 ATE432997 T1 AT E432997T1 AT 05710924 T AT05710924 T AT 05710924T AT 05710924 T AT05710924 T AT 05710924T AT E432997 T1 ATE432997 T1 AT E432997T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- amount
- treatment
- individual
- acc133
- Prior art date
Links
- 238000012544 monitoring process Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54945004P | 2004-03-02 | 2004-03-02 | |
| EP04075686A EP1571225A1 (de) | 2004-03-02 | 2004-03-02 | Diagnose von Krankheiten und Überwachung einer Therapie unter Verwendung des AC133 Gens |
| PCT/NL2005/000155 WO2005083123A1 (en) | 2004-03-02 | 2005-03-02 | Diagnosis of (a risk of) disease and monitoring of therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432997T1 true ATE432997T1 (de) | 2009-06-15 |
Family
ID=34746048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05710924T ATE432997T1 (de) | 2004-03-02 | 2005-03-02 | Therapieüberwachung für tumoren unter benutzung acc133 mrna |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP1571225A1 (de) |
| AT (1) | ATE432997T1 (de) |
| CA (1) | CA2558604A1 (de) |
| WO (1) | WO2005083123A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE515288T1 (de) * | 2004-09-24 | 2011-07-15 | Rfe Pharma Llc | Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen |
| US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
| WO2008003013A2 (en) * | 2006-06-29 | 2008-01-03 | Abbott Laboratories | Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic |
| US20080027008A1 (en) * | 2006-07-31 | 2008-01-31 | Jack Henkin | Antitumorigenic Drug Combination |
| US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| WO2010123626A1 (en) * | 2009-04-24 | 2010-10-28 | University Of Southern California | Cd133 polymorphisms and expression predict clinical outcome in patients with cancer |
| PL2729008T3 (pl) * | 2011-07-07 | 2017-10-31 | Res Cancer Institute Of America | Systemy, sposoby i formulacje do leczenia raka |
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2018170457A1 (en) | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| US12213958B2 (en) | 2017-11-17 | 2025-02-04 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| KR102138249B1 (ko) * | 2018-10-30 | 2020-07-27 | 서울대학교산학협력단 | 유방암 진단용 바이오마커 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002219707A1 (en) * | 2000-12-04 | 2002-06-18 | Primagen B.V. | Testing endosymbiont cellular organelles and compounds identifiable therewith |
| CA2439795A1 (en) * | 2001-03-07 | 2002-09-12 | Biomerieux B.V. | Method for the amplification and detection of dna using a transcription based amplification |
| WO2003066097A2 (en) * | 2002-02-08 | 2003-08-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | A novel target to inhibit angiogenesis |
| US7252976B2 (en) * | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
-
2004
- 2004-03-02 EP EP04075686A patent/EP1571225A1/de not_active Withdrawn
-
2005
- 2005-03-02 WO PCT/NL2005/000155 patent/WO2005083123A1/en not_active Ceased
- 2005-03-02 AT AT05710924T patent/ATE432997T1/de not_active IP Right Cessation
- 2005-03-02 EP EP05710924A patent/EP1725679B1/de not_active Expired - Lifetime
- 2005-03-02 CA CA002558604A patent/CA2558604A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1725679A1 (de) | 2006-11-29 |
| EP1725679B1 (de) | 2009-06-03 |
| CA2558604A1 (en) | 2005-09-09 |
| EP1571225A1 (de) | 2005-09-07 |
| WO2005083123A1 (en) | 2005-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE432997T1 (de) | Therapieüberwachung für tumoren unter benutzung acc133 mrna | |
| CA2735578C (en) | Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants | |
| ATE540319T1 (de) | Verfahren für die bestimmung von fk506 | |
| WO2008063413A3 (en) | Gene expression profiling for identification, monitoring, and treatment of lung cancer | |
| DE602004017426D1 (de) | Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression | |
| WO2007126758A3 (en) | Method and system for determining whether a drug will be effective on a patient with a disease | |
| DE60326214D1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
| EP2503338A3 (de) | CD73 als Biomarker zur Überwachung der Entwicklung von Krankheiten und zum Testen der Wirksamkeit von Therapien | |
| SG156625A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
| WO2006036744A3 (en) | Methods for a global assay of coagulation and fibrinolysis | |
| WO2006055524A3 (en) | Biomarkers for diagnosing schizophrenia and bipolar disorder | |
| WO2007016367A3 (en) | Neoplastic disease-related methods, kits, systems and databases | |
| WO2006113245A3 (en) | Methods for measuring glycan levels of proteins | |
| WO2005005661A3 (en) | Genes regulated in ovarian cancer as prognostic and therapeutic targets | |
| DE602006011607D1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| BRPI0414365A (pt) | composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes | |
| WO2007016532A3 (en) | Mutations and polymorphisms of hdac4 | |
| WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
| WO2006012468A3 (en) | Detection of oligonuleotides by dual hybridization | |
| WO2004113574A3 (en) | Methods for disease screening | |
| WO2008145701A9 (en) | Method for predicting the outcome of a critically ill patient | |
| DE50313393D1 (de) | Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1 | |
| DE602004027534D1 (de) | Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie | |
| WO2009068423A3 (en) | Method for predicting therapy responsiveness in basal like tumors | |
| WO2005058142A3 (en) | Diabetes diagnostic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |